After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Buying Yahoo!'s core assets is the start of something very big, Cramer says.
Amgen (AMGN) will report 2016 second quarter earnings on Wednesday, July 27 after the market close.
The Federal Reserve will steal focus from another onslaught of earnings in the coming week as investors remain wary over the central bank's rate-hike timetable.
A late-stage trial for Amgen’s (AMGN) drug ABP 980 shows its ‘non-inferiority’ to Roche’s (RHHBY) biosimilar branded product.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.